Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial

• DOI: 10.1016/j.omton.2025.200977
• Publication Date: 2025-03-27T00:38:18Z
• Authors: Hamenth Kumar Palani; Arun Kumar Arunac...; Uday Kulkarni; Mohammed Yasar; Arvind Venkatraman; Swathy Palanikumar; Reeshma Nair Radh...; Majeela Solomon; Abirami Rajasekaran; Aniket Bankar; Phaneendra Venkat...; Sushil Selvarajan; Anu Korula; Pradyot Dash; Dina Schneider; Louisa Wirthlin; Aby Abraham; Biju George; Vikram Mathews